Central airways remodeling in COPD patients

International Journal of COPD

Volumn 9, Issue , 2014, Pages 927-933

  Pini, Laura ^a   Pinelli, Valentina ^b   Modina, Denise ^a   Bezzi, Michela ^b   Tiberio, Laura ^a   Tantucci, Claudio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Department of Respiratory Medicine ^*  (Italy)

Author keywords

Airway smooth muscle; Central airways; COPD; Proteoglycans; Remodeling

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BIGLYCAN; COLLAGEN TYPE 1; DECORIN; SCLEROPROTEIN; VERSICAN; ACTA2 PROTEIN, HUMAN; ACTIN; PROTEOGLYCAN;

ADULT; AGED; AIRWAY OBSTRUCTION; AIRWAY REMODELING; ARTICLE; BRONCHUS BIOPSY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG FUNCTION; MALE; MORPHOMETRICS; PROTEIN EXPRESSION; SMOKING; SMOOTH MUSCLE; VERY ELDERLY; BIOPSY; BRONCHUS; CASE CONTROL STUDY; CHEMISTRY; EXTRACELLULAR MATRIX; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; VITAL CAPACITY;

ACTINS; ADULT; AGED; AGED, 80 AND OVER; AIRWAY REMODELING; BIOPSY; BRONCHI; CASE-CONTROL STUDIES; COLLAGEN TYPE I; EXTRACELLULAR MATRIX; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUSCLE, SMOOTH; PROTEOGLYCANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VITAL CAPACITY;

EID: 84907151557     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S52478     Document Type: Article

References (24)

1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-946.
2. Tam A, Sin DD. Pathobiologic mechanisms of chronic obstructive pulmonary disease. Med Clin North Am. 2012;96(4):681-698.
3. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med. 2001;164:S28-S38.
4. Rutgers SR, Timens W, Kauffman HF, Postma DS. Markers of active airway inflammation and remodelling in chronic obstructive pulmonary disease. Clin Exp Allergy. 2001;31(2):193-205.
5. Kuwano K, Bosken CH, Pare PD, Bai TR, Wiggs BR, Hogg JC. Small airways dimensions in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1993;148(5):1220-1225.
6. Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(3 Pt 1):822-826.
7. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645-2653.
8. Tiddens HA, Pare PD, Hogg JC, Hop WC, Lambert R, de Jongste JC. Cartilaginous airway dimensions and airflow obstruction in human lungs. Am J Respir Crit Care Med. 1995;152(1):260-266.
9. Liesker JJ, Ten Hacken NH, Zeinstra-Smith M, et al. Reticular basement membrane in asthma and COPD: similar thickness, yet different composition. Int J Chron Obstruct Pulmon Dis. 2009;4:127-135.
10. Kranenburg AR, Willems-Widyastuti A, Moori WJ, et al. Enhanced bronchial expression of extracellular matrix proteins in chronic obstructive pulmonary disease. Am J Clin Pathol. 2006;126:725-735.
11. Annoni R, Lancas T, Tanigawa R, et al. Extracellular matrix composition in COPD. Eur Respir J. 2012;40(6):1362-1373.
12. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem. 1998;67:609-652.
13. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6): 532-555.
14. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007;29(6):1224-1238.
15. Bolliger CT, Mathur PN, Beamis JF, et al. ERS/ATS statement on interventional pulmonology. Eur Respir J. 2002;19(2):356-373.
16. Pini L, Hamid Q, Shannon J, et al. Differences in proteoglycan deposition in the airways of moderate and severe asthmatics. Eur Respir J. 2007;29(1):71-77.
17. Bolender RP, Hyde DM, Dehoff RT. Lung morphometry: a new generation of tools and experiments for organ, tissue, cell, and molecular biology. Am J Physiol. 1993;265(6 Pt 1):L521-L548.
18. Weibel ER, Hsia CC, Ochs M. How much is there really? Why stereology is essential in lung morphometry. J Appl Physiol. 2007;102(1):459-467.
19. Garusi E, Rossi S, Perris R. Antithetic roles of proteoglycans in cancer. Cell Mol Life Sci. 2012;69:553-579.
20. Hasegawa M, Nasuhara Y, Onodera Y, et al. Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(12):1309-1315.
21. Ruoslahti E, Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell. 1991;64(5):867-869.
22. Bosken CH, Wiggs BR, Pare PD, Hogg JC. Small airway dimensions in smokers with obstruction to airflow. Am Rev Respir Dis. 1990;142(3): 563-570.
23. Cosio MG, Hale KA, Niewoehner DE. Morphologic and morphometric effects of prolonged cigarette smoking on the small airways. Am Rev Respir Dis. 1980;122(2):265-271.
24. Saetta M, Turato G, Baraldo S, et al. Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Am J Respir Crit Care Med. 2000;161(3 Pt 1):1016-1021.